CXXC4

Across TCGA pan-cancer cohorts, CXXC4 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CXXC4 data layer compared with 26 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher CXXC4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CXXC4 expression acts as an unfavorable survival marker.

LIHC, SCLC, and SKCM are the cancer types where CXXC4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.198	0.777	.006	18	view →
SCLC	DFS	Median	II,III,IV	0.137	0.602	.008	12	view →
SKCM	OS	Median	All	0.174	0.781	<.001	12	view →
LUSC	OS	Median	All	0.196	0.724	.049	6	view →
LUAD	OS	Median	All	0.206	0.684	.021	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CXXC4–LIHC (OS)

Open the LIHC breakdown →